Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement.
BACKGROUND
In-stent restenosis is notoriously difficult to treat by repeat catheter intervention because of its propensity for aggressive recurrent neointimal formation. This study sought to assess the effectiveness and safety of the sirolimus-eluting stent in the treatment of in-stent restenosis.


RESULTS
The study was designed as a prospective multicenter registry. We included 162 patients with in-stent restenosis of a native coronary artery who had a clinical indication for repeat intervention. Patients were scheduled for follow-up angiography at 6 months. The primary end point was in-lesion late loss. Follow-up angiography was performed in 155 patients. We obtained an in-lesion late loss of 0.08+/-0.49 mm and a binary restenosis rate of 9.7% (15/155), which prompted reintervention in 7.4% (12/162) at 9 months. The 9-month rate of death was 1.2% (2/162) and that of nonfatal myocardial infarction was 1.2% (2/162).


CONCLUSIONS
Sirolimus-eluting stents were highly efficacious and safe in the treatment of in-stent restenosis. Our study provides rationale for the use of sirolimus-eluting stents in the treatment of in-stent restenosis.
Neumann
Franz-Josef
FJ
Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany. franz-josef.neumann@herzzentrum.de
Desmet
Walter
W
Grube
Eberhard
E
Brachmann
Johannes
J
Presbitero
Patrizia
P
Rubartelli
Paolo
P
Mügge
Andreas
A
Di Pede
Francesco
F
Füllgraf
Diana
D
Aengevaeren
Wim
W
Spedicato
Leonardo
L
Popma
Jeffrey J
JJ
D000368:Aged; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D015996:Survival Rate; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus